<DOC>
	<DOCNO>NCT00928967</DOCNO>
	<brief_summary>To evaluate evolution impact daily life activity first 12 month follow introduction interferon beta-1b treatment patient present RRMS patient high risk develop Multiple Sclerosis first clinical demyelinating event</brief_summary>
	<brief_title>Open , Multicentric , Prospective , Quality Life Study Multiple Sclerosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Males female age 18 year , receive confirmed diagnosis RRMS define MacDonald Poser criterion first clinical demyelinate event suggestive Multiple Sclerosis , meeting requirement study inclusion criterion The choice treatment must clearly dissociate decision include patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Quality life</keyword>
</DOC>